UNSPSC 51281601: Bluensomycin

This classification denotes an aminoglycoside antibiotic with the molecular formula C21H39N5O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LWV7PWE57U, chemically known as d-scyllo-inositol, o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1=>2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1=>2)-1-((aminoiminomethyl)amino)-1-deoxy-, 5-carbamate but generally known as bluensomycin, which bears US NIH Compound Identifier 65603. Bluensomycin most often comes in base and sulfate forms.

UNSPSC 51281601 Bluensomycin (Commodity) does not align with the recent state and local procurement activity tagged under this code. The four opportunities posted between January and June 2026 solicit naloxone and drug deactivation systems, therapeutic pharmacy initiative programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products—none of which are bluensomycin or related to the specific pharmaceutical this code nominally describes. The mismatch suggests either a taxonomy classification error in the source data or that bluensomycin procurement does not drive material recent activity in state and local markets.

The recent opportunities show demand across health departments, emergency services, and cooperative purchasing vehicles. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023 per the source, though dates appear inconsistent) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 to explore direct-to-manufacturer prescription programs. The City of Tampa's Purchasing Department released an IFB on March 25, 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, designated as a sheltered market for certified Small Local Business Enterprises with a 5% bid discount, capped at $10,000, and an estimated contract value of $700,000. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP on January 20, 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, requiring vendors to work through three authorized wholesalers with pricing weighted 75 percent in evaluation. Activity spans Florida, Texas, Minnesota, and multi-state cooperative membership; however, none of these solicitations appear substantively related to bluensomycin as a product category.